In a phase I/II clinical trial of patients with advanced HCC who were previously treated with sorafenib, the regimen of tremelimumab (anti-CTLA4, 1500 mg) plus durvalumab (anti-PD-L1, 300 mg) every 4 weeks produced an ORR of 24% with a median OS of 18.7 months (17) (Table 1). This evidence concerns the gene CD274 and hepatocellular carcinoma.